WASHINGTON, D.C. - A New Jersey federal judge's construction of the terms "alkaline salt" and "pharmaceutically acceptable salt" in two patents relating to the heartburn drug Nexium was not erroneous, the Federal Circuit U.S. Court of Appeals ruled Dec. 19 (AstraZeneca AB et al. v. Hanmi USA Inc., No. 13-1490, Fed. Cir.).